Last reviewed · How we verify
hcg hormone
hcg hormone is a Small molecule drug developed by mostafa gomaa hamid halawa. It is currently in Phase 2 development. Also known as: pregnyl.
Here's a 2-sentence factual summary of hCG hormone based on the provided facts: hCG hormone is a parathyroid hormone/parathyroid hormone-related peptide receptor agonist, classified as a protein-based drug. It is used to treat reproductive issues, fertility disorders, and gynecologic diseases, often in combination with other interventions such as Follitropin Alfa or Follicle Stimulating Hormone/Luteinizing Hormone.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | hcg hormone |
|---|---|
| Also known as | pregnyl |
| Sponsor | mostafa gomaa hamid halawa |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids (PHASE1, PHASE2)
- Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study
- Isotretinoin vs hCG for Male Infertility Due to Low or Absent Sperm (PHASE2)
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
- Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome (PHASE2)
- Experimental Study on the Use of Intrauterine Infusion of Autologous Platelet-rich Plasma (PRGF-IUI) in Patients With Recurrent Implantation Failure and/or Refractory Thin Endometrium (NA)
- Assessment of the Feasibility of Frozen Embryo Transfers in a Natural Cycle Among Obese Compared to Non-Obese Patients
- Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hcg hormone CI brief — competitive landscape report
- hcg hormone updates RSS · CI watch RSS
- mostafa gomaa hamid halawa portfolio CI
Frequently asked questions about hcg hormone
What is hcg hormone?
Who makes hcg hormone?
Is hcg hormone also known as anything else?
What development phase is hcg hormone in?
Related
- Manufacturer: mostafa gomaa hamid halawa — full pipeline
- Also known as: pregnyl
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing